Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376152 | 1.00 | TSHR (0.48) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL20260209 | 0.82 | TSHR (0.41) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL4974578 | 0.80 | ALDH1A1 (0.40) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL29375771 | 0.80 | TSHR (0.48) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL41990 | 0.80 | TSHR (0.48) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL4882904 | 0.79 | TP53 (0.52) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL391628 | 0.78 | CA2 (0.42) | ALDH1A1TDP1CYP3A4TP53MEN1 | |
| SCHEMBL246398 | 0.78 | ENPP2 (0.42) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL31208432 | 0.78 | ENPP2 (0.42) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL1349122 | 0.78 | CYP3A4 (0.48) | ALDH1A1CYP3A4ENPP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 849 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| CN-113956233-A | Amide compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 南方医科大学 | 2022-01-21 | — | — | CN | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-RE50527-E1 | Covalent inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250134890-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2025-05-01 | — | — | US | disclosed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| US-12232516-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12193465-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118206427-A | Preparation method of 2,2', 5' -tetrachlorobiphenyl | 上海泰坦科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024043334-A1 | NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | disclosed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230329092-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11737481-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023152042-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023114977-A1 | S1PR4 RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | TIAKI THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-110573494-B | Novel heterocyclic compound and organic light-emitting device comprising same | 株式会社LG化学 | 2023-05-12 | — | — | CN | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| CN-115850021-A | Preparation method of polychlorinated biphenyl standard substance | 上海安谱实验科技股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-112239475-B | Nitrogen-containing compound, electronic component, and electronic device | 陕西莱特光电材料股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| CN-115448938-A | Luminescent material, application thereof and organic electroluminescent device comprising luminescent material | 清华大学 | 2022-12-09 | — | — | CN | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3679023-B1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2022-11-02 | — | — | EP | disclosed |
| EP-3679024-B1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2022-11-02 | — | — | EP | disclosed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11401286-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114835688-A | Substituted 4-aryl imidazole-2-ketone derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-4015515-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT Materials Co., Ltd. (KR) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022078428-A1 | COMPOUND AS PROLYL HYDROXYLASE INHIBITOR AND PREPARATION METHOD THEREFOR | 江苏苏中药业集团股份有限公司 | 2022-04-21 | — | — | WO | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3976009-A2 | BAX INHIBITORS AND USES THEREOF | Case Western Reserve University (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11279709-B2 | Specifically substituted aza-dibenzofurans and aza-dibenzothiophenes for organic electronic devices | IDEMITSU KOSAN CO., LTD. (JP) | 2022-03-22 | — | — | US | disclosed |
| CN-108884059-B | Compound and organic light-emitting element using same | 株式会社LG化学 | 2022-03-18 | — | — | CN | disclosed |
| CN-114174298-A | Pyridazinone pyrimidine derivative and medical application thereof | 正大天晴药业集团南京顺欣制药有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-112011052-B | Functional boron-containing polyarylene sulfide copolymer and preparation method thereof | 四川大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-113956233-A | Amide compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 南方医科大学 | 2022-01-21 | — | — | CN | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3842420-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| CN-112534593-A | Organic light emitting diode | 株式会社LG化学 | 2021-03-19 | — | — | CN | disclosed |
| CN-107635970-B | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| WO-2021034039-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 엘티소재주식회사 | 2021-02-25 | — | — | WO | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20210040038-A1 | NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LG CHEM, LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| CN-112239475-A | Nitrogen-containing compound, electronic component, and electronic device | 陕西莱特光电材料股份有限公司 | 2021-01-19 | — | — | CN | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
| CN-112011052-A | Functional boron-containing polyarylene sulfide copolymer and preparation method thereof | 四川大学 | 2020-12-01 | — | — | CN | disclosed |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2020-11-12 | — | — | US | disclosed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283386-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-2881397-B1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | UNIV KYOTO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| EP-3670514-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-107074783-B | Hydroxyalkyl substituted phenyl triazole derivatives and uses thereof | 拜耳制药股份公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-3266779-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2020-06-03 | — | — | EP | disclosed |
| CN-107406471-B | Heterocyclic compound and organic light-emitting element comprising same | 株式会社LG化学 | 2020-06-02 | — | — | CN | disclosed |
| EP-3288936-B1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| CN-107406472-B | Heterocyclic compound and organic light-emitting device comprising same | 株式会社LG化学 | 2020-03-27 | — | — | CN | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| CN-106986865-B | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | 国立大学法人京都大学 | 2020-02-28 | — | — | CN | disclosed |
| US-10570120-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570120-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3266780-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2020-02-19 | — | — | EP | disclosed |
| EP-3266780-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2020-02-19 | — | — | EP | disclosed |
| CN-110573494-A | Novel heterocyclic compound and organic light-emitting device comprising same | 株式会社LG化学 | 2019-12-13 | — | — | CN | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-2730634-B1 | NOVEL COMPOUND AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEMICAL LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| EP-2730634-B1 | NOVEL COMPOUND AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEMICAL LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-20190248804-A1 | SPECIFICALLY SUBSTITUTED AZA-DIBENZOFURANS AND AZA-DIBENZOTHIOPHENES FOR ORGANIC ELECTRONIC DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190248804-A1 | SPECIFICALLY SUBSTITUTED AZA-DIBENZOFURANS AND AZA-DIBENZOTHIOPHENES FOR ORGANIC ELECTRONIC DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| US-10364258-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-10355225-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-10355225-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
| EP-2978756-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Pharma AG (DE) | 2019-03-27 | — | — | EP | disclosed |
| WO-2019048443-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019048458-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-03-14 | — | — | WO | disclosed |
| US-20190055269-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2019-02-21 | — | — | US | disclosed |
| US-10189823-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189823-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| WO-2019004617-A1 | NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2019-01-03 | — | — | WO | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| EP-2882716-B9 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-12-26 | — | — | EP | disclosed |
| EP-3081553-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIV TSUKUBA (JP) | 2018-12-12 | — | — | EP | disclosed |
| EP-2858650-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-3401314-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10123984-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-13 | — | — | US | disclosed |
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10093686-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20180237423-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3215498-B1 | HYDROXYALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma AG (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-10053417-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-06-21 | — | — | US | disclosed |
| EP-3056207-B1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMA CO LTD (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| EP-3333169-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9972784-B2 | Compounds and organic electronic device using same | LG CHEM, LTD. (KR) | 2018-05-15 | — | — | US | disclosed |
| US-9972784-B2 | Compounds and organic electronic device using same | LG CHEM, LTD. (KR) | 2018-05-15 | — | — | US | disclosed |
| US-9972784-B2 | Compounds and organic electronic device using same | LG CHEM, LTD. (KR) | 2018-05-15 | — | — | US | disclosed |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-04-26 | — | — | US | disclosed |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-04-26 | — | — | US | disclosed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | disclosed |
| US-9944640-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-04-17 | — | — | US | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| WO-2018043761-A1 | SPECIFICALLY SUBSTITUTED AZA-DIBENZOFURANS AND AZA-DIBENZOTHIOPHENES FOR ORGANIC ELECTRONIC DEVICES | IDEMITSU KOSAN CO.,LTD. (JP) | 2018-03-08 | — | — | WO | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-3288936-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873696-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873685-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873685-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873685-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3266780-A2 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG Chem, Ltd. (KR) | 2018-01-10 | — | — | EP | disclosed |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-9840460-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349574-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2017-11-30 | — | — | US | disclosed |
| US-9822102-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170327459-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-16 | — | — | US | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-9815787-B2 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20170313665-A1 | HYDROXYALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-02 | — | — | US | disclosed |
| EP-3013823-B1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-9777024-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-9771352-B2 | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| EP-3215498-A1 | HYDROXYALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170217959-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217961-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-08-03 | — | — | US | disclosed |
| EP-2134684-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| CN-106986865-A | On Mental disease or the compound and medical composition of malignant tumour | 国立大学法人京都大学 | 2017-07-28 | — | — | CN | disclosed |
| EP-3193851-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-07-13 | — | — | US | disclosed |
| US-9688616-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9682052-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2311826-B1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEMICAL LTD (KR) | 2017-05-24 | — | — | EP | disclosed |
| EP-2311826-B1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEMICAL LTD (KR) | 2017-05-24 | — | — | EP | disclosed |
| US-9656971-B2 | COMT inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2964616-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-3151833-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| CN-104520303-B | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | 国立大学法人京都大学 | 2017-04-12 | — | — | CN | disclosed |
| US-9604937-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-03-28 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| EP-2773335-B1 | OXALIC ACID AMIDES AS NEPRILYSIN INHIBITORS, PHARMACEUTICAL COMPOSITION THEREOF AND PREPARATION THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555041-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2938600-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20170015619-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-19 | — | — | US | disclosed |
| EP-2570412-B1 | Novel nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEMICAL LTD (KR) | 2017-01-04 | — | — | EP | disclosed |
| EP-2570412-B1 | Novel nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEMICAL LTD (KR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-2882716-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2882716-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2016176449-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| EP-2556066-B1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-3081553-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-9434690-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9428457-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| EP-2594557-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594556-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2735561-B1 | Substituted carbamoylmethoxyacetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2016-07-20 | — | — | EP | disclosed |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152609-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160152609-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| EP-2640375-B1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2016-05-18 | — | — | EP | disclosed |
| WO-2016071212-A1 | HYDROXYALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122325-A1 | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-05 | — | — | US | disclosed |
| EP-2719742-B1 | NOVEL COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEMICAL LTD (KR) | 2016-04-27 | — | — | EP | disclosed |
| EP-2719742-B1 | NOVEL COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEMICAL LTD (KR) | 2016-04-27 | — | — | EP | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160074352-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2978756-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2970121-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2964616-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002177-A1 | COMT INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2016-01-07 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150376128-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-31 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2938600-A1 | COMT INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2925744-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2015-10-07 | — | — | EP | disclosed |
| US-9150500-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| US-9139562-B2 | Nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEM, LTD. (KR) | 2015-09-22 | — | — | US | disclosed |
| US-9139562-B2 | Nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEM, LTD. (KR) | 2015-09-22 | — | — | US | disclosed |
| US-9139562-B2 | Nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEM, LTD. (KR) | 2015-09-22 | — | — | US | disclosed |
| US-9133158-B2 | Bicyclic dihydroisoquinoline-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9126956-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126956-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126956-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| EP-2912019-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9120758-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120758-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120758-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2651900-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2651900-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-9096496-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9073881-B2 | Benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-20150166469-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2882716-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2881397-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | Kyoto University (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152117-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-9035047-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2858650-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-04-15 | — | — | EP | disclosed |
| CN-104520303-A | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | NAT UNIV CORP KYOTO UNIV | 2015-04-15 | — | — | CN | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8999998-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000169-B2 | Compounds and organic electronic device using the same | LG CHEM, LTD. (KR) | 2015-04-07 | — | — | US | disclosed |
| US-9000169-B2 | Compounds and organic electronic device using the same | LG CHEM, LTD. (KR) | 2015-04-07 | — | — | US | disclosed |
| US-9000169-B2 | Compounds and organic electronic device using the same | LG CHEM, LTD. (KR) | 2015-04-07 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-8956999-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| WO-2014066659-A9 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS, LLC. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015019037-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
| WO-2014209978-A1 | IMIDAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2014-12-31 | — | — | WO | disclosed |
| US-8901169-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140343138-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8877786-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2794597-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-29 | — | — | EP | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014154794-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| WO-2014138053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2773335-A1 | NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| WO-2014106606-A1 | NOVE PHENYL/PYRIDINE SERIES SUBSTITUED BY HYDROXYETHYLAMINO FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-10 | — | — | WO | disclosed |
| WO-2014102233-A1 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-03 | — | — | WO | disclosed |
| US-8759590-B2 | Indenopyrene compound, organic thin film solar cell material using the same, and organic thin film solar cell | IDEMITSU KOSAN CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| EP-2735561-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | Novartis AG (CH) | 2014-05-28 | — | — | EP | disclosed |
| EP-2730634-A2 | NOVEL COMPOUND AND ORGANIC ELECTRONIC DEVICE USING SAME | LG Chem, Ltd. (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730634-A2 | NOVEL COMPOUND AND ORGANIC ELECTRONIC DEVICE USING SAME | LG Chem, Ltd. (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| WO-2014066659-A1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS, LLC. (US) | 2014-05-01 | — | — | WO | disclosed |
| US-8709489-B2 | Emulsions containing arylboronic acids and medical articles made therefrom | SURMODICS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140110694-A1 | NOVEL COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEM, LTD. (KR) | 2014-04-24 | — | — | US | disclosed |
| US-20140110694-A1 | NOVEL COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEM, LTD. (KR) | 2014-04-24 | — | — | US | disclosed |
| US-20140110694-A1 | NOVEL COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEM, LTD. (KR) | 2014-04-24 | — | — | US | disclosed |
| EP-2501683-B1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | NOVARTIS AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2719742-A2 | NOVEL COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING SAME | LG Chem, Ltd. (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20140088165-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-03-27 | — | — | US | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-8642635-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2014-02-04 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| WO-2013184898-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| US-20130330365-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-12-12 | — | — | US | disclosed |
| EP-2670738-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| EP-2173727-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| EP-2651900-A1 | NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2640375-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-1924563-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | HOFFMANN LA ROCHE (CH) | 2013-07-31 | — | — | EP | disclosed |
| EP-1924563-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | HOFFMANN LA ROCHE (CH) | 2013-07-31 | — | — | EP | disclosed |
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20130181196-A1 | COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2013-07-18 | — | — | US | disclosed |
| US-20130181196-A1 | COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2013-07-18 | — | — | US | disclosed |
| US-20130181196-A1 | COMPOUNDS AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2013-07-18 | — | — | US | disclosed |
| WO-2013093484-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | WO | disclosed |
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8445679-B2 | 7-substituted indole MCL-1 inhibitors | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2013067163-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096168-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| WO-2013041468-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2013-03-28 | — | — | US | disclosed |
| US-8404708-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2570412-A1 | Novel nitrogen-containing heterocyclic compound and organic electronic device using the same | LG Chem, Ltd. (KR) | 2013-03-20 | — | — | EP | disclosed |
| EP-2570412-A1 | Novel nitrogen-containing heterocyclic compound and organic electronic device using the same | LG Chem, Ltd. (KR) | 2013-03-20 | — | — | EP | disclosed |
| US-8399459-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| WO-2013029338-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-8377978-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2013-02-19 | — | — | US | disclosed |
| EP-2556066-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-02-13 | — | — | EP | disclosed |
| US-8368062-B2 | Nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEM, LTD. (KR) | 2013-02-05 | — | — | US | disclosed |
| US-8368062-B2 | Nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEM, LTD. (KR) | 2013-02-05 | — | — | US | disclosed |
| US-8368062-B2 | Nitrogen-containing heterocyclic compound and organic electronic device using the same | LG CHEM, LTD. (KR) | 2013-02-05 | — | — | US | disclosed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2013009013-A2 | NOVEL COMPOUND AND ORGANIC ELECTRONIC DEVICE USING SAME | 주식회사 엘지화학 (KR) | 2013-01-17 | — | — | WO | disclosed |
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| EP-2501683-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | Novartis AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| US-8263629-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263629-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20120202862-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012104263-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196915-A1 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process | ARGON PHARMA, S.L. (ES) | 2012-08-02 | — | — | US | disclosed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
| EP-2016039-B1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO MCNEIL JANSSEN PHARM (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8222286-B2 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-8211913-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082857-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082857-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2459532-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | Argon Pharma S.L. (ES) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012065958-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2448941-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2012052395-A1 | ISOXAZOLE DERIVATIVES USED AS OESTROGEN MODULATORS | N. V. ORGANON (NL) | 2012-04-26 | — | — | WO | disclosed |
| EP-2435409-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| US-8143307-B2 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-27 | — | — | US | disclosed |
| US-20120068123-A1 | USE OF PHTHALOCYANINE COMPOUNDS WITH ARYL OR HETARYL SUBSTITUENTS IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| US-8106236-B2 | Triaryl compounds and derivates thereof | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20120007069-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2012-01-12 | — | — | US | disclosed |
| US-20120007069-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2012-01-12 | — | — | US | disclosed |
| US-20120007069-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2012-01-12 | — | — | US | disclosed |
| WO-2011124580-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110240125-A1 | INDENOPYRENE COMPOUND, ORGANIC THIN FILM SOLAR CELL MATERIAL USING THE SAME, AND ORGANIC THIN FILM SOLAR CELL | IDEMITSU KOSAN CO., LTD. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| EP-1945630-B1 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2011-09-21 | — | — | EP | disclosed |
| US-20110178055-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2011-07-21 | — | — | US | disclosed |
| US-7981914-B2 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-20110127513-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2011-06-02 | — | — | US | disclosed |
| US-20110127513-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2011-06-02 | — | — | US | disclosed |
| US-20110127513-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG CHEM, LTD. (KR) | 2011-06-02 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110124695-A1 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| WO-2011061271-A1 | SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS | NOVARTIS AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-7939533-B2 | Dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2316816-A1 | INDENOPYRENE COMPOUND, ORGANIC THIN FILM SOLAR CELL MATERIAL USING THE SAME, AND ORGANIC THIN FILM SOLAR CELL | Idemitsu Kosan Co., Ltd. (JP) | 2011-05-04 | — | — | EP | disclosed |
| EP-2311826-A2 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | LG Chem, Ltd. (KR) | 2011-04-20 | — | — | EP | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076337-A1 | EMULSIONS CONTAINING ARYLBORONIC ACIDS AND MEDICAL ARTICLES MADE THEREFROM | BANK OF MONTREAL, AS COLLATERAL AGENT | 2011-03-31 | — | — | US | disclosed |
| US-7915271-B2 | 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2284154-A1 | Antitumor 1,2-diphenylpyrrole compounds and their preparation process | Argon Pharma S.L. (ES) | 2011-02-16 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| WO-2011012660-A1 | ANTITUMOR 1,2-DIPHENYLPYRROLE COMPOUNDS AND THEIR PREPARATION PROCESS | ARGON PHARMA, S. L. (ES) | 2011-02-03 | — | — | WO | disclosed |
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136493-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100279868-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7825104-B2 | Methods and compositions for treating fungal infections | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-11-02 | — | — | US | disclosed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7799818-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2225248-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Wyeth LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| EP-1399445-B9 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2205573-A1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2198867-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | Vertex Pharmaceuticals, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2010054253-A1 | TRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054260-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1474147-B1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1474147-B1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| EP-2173727-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-7691493-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7691493-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2010-04-06 | — | — | US | disclosed |
| EP-2167091-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-01-07 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090325916-A1 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2134684-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622492-B2 | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-7598285-B2 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7592356-B2 | Triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-22 | — | — | US | disclosed |
| US-7592356-B2 | Triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-22 | — | — | US | disclosed |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1831192-A4 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7571894-B2 | Organic electroluminescence element | FUJI PHOTO FILM CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7571894-B2 | Organic electroluminescence element | FUJI PHOTO FILM CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| EP-1399445-B1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090176854-A1 | N-[4-((1S)-1-{3-(3,5-Dichlorophenyl)-5-[6-(trifluoromethoxy)-2-naphthyl]-1H-pyrazol-1-yl}ethyl)benzoyl]- beta -alanine; type 2 diabetes, hyperglycemia, or insulin resistance | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090149503-A1 | NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES | AMREIN KURT | 2009-06-11 | — | — | US | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070583-A1 | PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090137806-A1 | DUAL NK1/NK3 RECEPTOR ANTAGONISTS | HOFFMANN TORSTEN | 2009-05-28 | — | — | US | disclosed |
| US-20090137548-A1 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-05-28 | — | — | US | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7528159-B2 | 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| WO-2009043780-A1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-7511061-B2 | Triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-7511061-B2 | Triazoles as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090036454-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| US-20090029855-A1 | Quinoline Derivatives and Their Use as Pesticides | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| US-7482341-B2 | N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-2016039-A1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20090018112-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | disclosed |
| EP-2007727-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS PESTICIDES | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2009000533-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155573-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
| US-7442760-B2 | Electroactive polymers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442760-B2 | Electroactive polymers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442760-B2 | Electroactive polymers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1973877-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008111794-A1 | 4-METHYLIMIDAZOL-5-YLCARBONYLGUANIDINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE ISCHEMIC HEART DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008109697-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| EP-1966158-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1966132-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7414142-B2 | 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2008082567-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK & CO., INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1789041-B1 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| US-20080153802-A1 | Alpha-helical mimetics | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2008-06-26 | — | — | US | disclosed |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1924563-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-20080119537-A1 | 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1756064-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008052075-A2 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103150-A1 | Triazoles as Farnesyl Transferase Inhibitors | SAHA ASHIS K | 2008-05-01 | — | — | US | disclosed |
| US-20080103150-A1 | Triazoles as Farnesyl Transferase Inhibitors | SAHA ASHIS K | 2008-05-01 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1628979-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20080026135-A1 | ELECTRON TRANSPORT AGENTS FOR ORGANIC ELECTRONIC DEVICES | 3M INNOVATIVE PROPERTIES COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080026135-A1 | ELECTRON TRANSPORT AGENTS FOR ORGANIC ELECTRONIC DEVICES | 3M INNOVATIVE PROPERTIES COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080026135-A1 | ELECTRON TRANSPORT AGENTS FOR ORGANIC ELECTRONIC DEVICES | 3M INNOVATIVE PROPERTIES COMPANY | 2008-01-31 | — | — | US | disclosed |
| EP-1881827-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2008-01-30 | — | — | EP | disclosed |
| EP-1687288-B1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7319152-B2 | Contraception, hormone replacement therapy, cycle-related symptoms, or benign or malignant neoplastic disease; -methyl-5-(5-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrrole-2-carbonitrile | WYETH (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1874756-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-20070257604-A1 | POLYMERIC COMPOUND AND ORGANIC LUMINESCENCE DEVICE | CANON KABUSHIKI KAISHA (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070257604-A1 | POLYMERIC COMPOUND AND ORGANIC LUMINESCENCE DEVICE | CANON KABUSHIKI KAISHA (JP) | 2007-11-08 | — | — | US | disclosed |
| WO-2007124351-A1 | TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254957-A1 | TRIARYL COMPOUNDS AND DERIVATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| WO-2007104726-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS PESTICIDES | BASF SE (DE) | 2007-09-20 | — | — | WO | disclosed |
| US-7271406-B2 | Electron transport agents for organic electronic devices | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271406-B2 | Electron transport agents for organic electronic devices | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271406-B2 | Electron transport agents for organic electronic devices | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1831192-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Korea Research Institute of Chemical Technology (KR) | 2007-09-12 | — | — | EP | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1643998-B1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2006037501-A9 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | HOFFMANN LA ROCHE (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007084450-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-7238690-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238435-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238435-B2 | Polymeric compound and organic luminescence device | CANON KABUSHIKI KAISHA (JP) | 2007-07-03 | — | — | US | disclosed |
| WO-2007073283-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1799647-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066675-A1 | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| EP-1756064-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
| WO-2006116165-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114606-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| US-7094902-B2 | Electroactive polymers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060178362-A1 | Substituted heterocyle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2006-08-10 | — | — | US | disclosed |
| EP-1687288-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-08-09 | — | — | EP | disclosed |
| US-7081455-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060155106-A1 | ELECTROACTIVE POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY | 2006-07-13 | — | — | US | disclosed |
| EP-1678154-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006071047-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-06 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1673059-A2 | ALKANOL AND CYCLOALKANOL-AMINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1673090-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1673084-A1 | 1-2' (1,4'-BIPERIDIN-1'-YL)-1-(PHENYL)-ETHYLCYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | disclosed |
| WO-2006037501-A1 | ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| EP-1643998-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1628979-A1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| EP-1618169-A1 | ELECTRON TRANSPORT AGENTS FOR ORGANIC ELECTRONIC DEVICES | 3M Innovative Properties Company (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005121097-A2 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2005-12-08 | — | — | US | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| EP-1573789-A2 | ELECTROACTIVE POLYMERS | 3M Innovative Properties Company (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037283-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003127-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF CXCR3 FUNCTION | CELLTECH R & D LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004101568-A1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004102615-A2 | ELECTROACTIVE POLYMERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040229859-A1 | Beta-amino acid compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-18 | — | — | US | disclosed |
| WO-2004096948-A1 | ELECTRON TRANSPORT AGENTS FOR ORGANIC ELECTRONIC DEVICES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1474147-A1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040220146-A1 | Methods and compositions for treating fungal infections | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2004-11-04 | — | — | US | disclosed |
| US-20040214036-A1 | Electron transport agents for organic electronic devices | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-21 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| EP-1189905-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6794386-B2 | β-amino acid compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-6777406-B2 | SUCH AS PYRIDO(3,2,1-IJ)PYRROLO(3,4-C)QUINOLIN-8-ONE DERI-VATIVES; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040127482-A1 | Administering substituted heterocycle fused gamma-carboline compounds for therapy of addictive behavior associated with 5HT2C receptor modulation | ROBICHAUD ALBERT J (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2004-05-13 | — | — | US | disclosed |
| US-20040062930-A1 | Electroactive polymers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | disclosed |
| US-20040029883-A1 | Beta-amino acid compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
| US-20030199526-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-23 | — | — | US | disclosed |
| EP-0966448-B1 | PYRAZINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2003-10-01 | — | — | EP | disclosed |
| US-6599905-B2 | Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-29 | — | — | US | disclosed |
| WO-2003049739-A1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | VERTEX PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| US-6548493-B1 | Serotonin receptor modulators (5-HT2C and 5-HT2A); treating obesity, anxiety, depression, psychological disorders, migraine, sexual disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20030022904-A1 | Pyrazine compounds | GLAXO WELLCOME INC. | 2003-01-30 | — | — | US | disclosed |
| US-6503909-B1 | Administering as antiepileptic or anticonvulsant agents; treating central nervous system disorders with dihydrofolate reductase inhibitors; side effect reduction | SMITHKLINE BEECHAM CORPORATION | 2003-01-07 | — | — | US | disclosed |
| US-20020169172-A1 | Pyrazine compounds | GLAXO WELLCOME INC. | 2002-11-14 | — | — | US | disclosed |
| EP-1246800-A1 | BETA-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2002-10-09 | — | — | EP | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1189905-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001047887-A1 | β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
| US-6255307-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | GLAXO WELLCOME, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-1107960-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-1049662-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000027394-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000012488-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| US-6017917-A | Guanidine derivatives | FUJISAWA PHARAMCEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0966448-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
| EP-0876338-A1 | GUANIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998038174-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| EP-0626016-B1 | CHEMILUMINESCENT ENHANCERS | BRITISH TECH GROUP (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997025310-A1 | GUANIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-17 | — | — | WO | disclosed |
| US-5629168-A | Chemiluminescent enhancers | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-05-13 | — | — | US | disclosed |
| EP-0626016-A1 | CHEMILUMINESCENT ENHANCERS | BTG INTERNATIONAL LIMITED (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016195-A1 | CHEMILUMINESCENT ENHANCERS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-08-19 | — | — | WO | disclosed |
| WO-1993016195-A1 | CHEMILUMINESCENT ENHANCERS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | TSHR 3456/4885ALDH1A1 4585/4885HSD17B10 3457/4885 |
| US-20140011997-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 1101/4885ALDH1A1 2644/4885HSD17B10 3448/4885 |
| US-20190270759-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | TSHR 3245/4885ALDH1A1 1152/4885HSD17B10 201/4885 |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 1031/4885ALDH1A1 2945/4885HSD17B10 3646/4885 |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | TSHR 2230/4885ALDH1A1 1703/4885HSD17B10 4115/4885 |
| US-20180114923-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | TSHR 3983/4885ALDH1A1 750/4885HSD17B10 2882/4885 |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | PDE12, PDE5A, PDE3A | TSHR 2416/4885ALDH1A1 1079/4885HSD17B10 188/4885 |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TSHR 4658/4885ALDH1A1 3259/4885HSD17B10 433/4885 |
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | TSHR 4868/4885ALDH1A1 2007/4885HSD17B10 2068/4885 |
| US-20050272794-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | TSHR 2959/4885ALDH1A1 1729/4885HSD17B10 688/4885 |
| US-20140256702-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 931/4885ALDH1A1 3584/4885HSD17B10 3918/4885 |
| US-20180237423-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 807/4885ALDH1A1 2776/4885HSD17B10 4056/4885 |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | TSHR 2230/4885ALDH1A1 1703/4885HSD17B10 4115/4885 |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | TSHR 316/4885ALDH1A1 3880/4885HSD17B10 3184/4885 |
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | TSHR 607/4885ALDH1A1 1519/4885HSD17B10 2089/4885 |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | TSHR 932/4885ALDH1A1 1375/4885HSD17B10 2278/4885 |
| US-20040029883-A1 | Beta-amino acid compounds as integrin antagonists | ITGB2, ITGA2, ITGA2B | TSHR 1273/4885ALDH1A1 2022/4885HSD17B10 3331/4885 |
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | TSHR 2993/4885ALDH1A1 1527/4885HSD17B10 1353/4885 |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | TSHR 932/4885ALDH1A1 1375/4885HSD17B10 2278/4885 |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | TSHR 2647/4885ALDH1A1 445/4885HSD17B10 280/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TSHR 4658/4885ALDH1A1 3259/4885HSD17B10 433/4885 |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 1047/4885ALDH1A1 2394/4885HSD17B10 4111/4885 |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | TSHR 467/4885ALDH1A1 1740/4885HSD17B10 270/4885 |
| US-20060074237-A1 | N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD11B2 | TSHR 1406/4885ALDH1A1 210/4885HSD17B10 10/4885 |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | TSHR 3700/4885ALDH1A1 127/4885HSD17B10 1093/4885 |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | TSHR 3245/4885ALDH1A1 1152/4885HSD17B10 201/4885 |
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | DPYD, MTHFD1, TYMS | TSHR 3846/4885ALDH1A1 120/4885HSD17B10 890/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 1031/4885ALDH1A1 2945/4885HSD17B10 3646/4885 |
| US-20160002177-A1 | COMT INHIBITORS | COMT, PNMT, SLC6A3 | TSHR 1833/4885ALDH1A1 92/4885HSD17B10 448/4885 |
| US-20190248804-A1 | SPECIFICALLY SUBSTITUTED AZA-DIBENZOFURANS AND AZA-DIBENZOTHIOPHENES FOR ORGANIC ELECTRONIC DEVICES | CDY1; CDY1B, CDYL, CBX8 | TSHR 482/4885ALDH1A1 1323/4885HSD17B10 4140/4885 |
| US-20030199526-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | TSHR 4533/4885ALDH1A1 2610/4885HSD17B10 1570/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | TSHR 3150/4885ALDH1A1 244/4885HSD17B10 1356/4885 |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | HTR3A, MAOA, GLS | TSHR 2992/4885ALDH1A1 489/4885HSD17B10 339/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | TSHR 2806/4885ALDH1A1 1252/4885HSD17B10 1498/4885 |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | TSHR 72/4885ALDH1A1 2512/4885HSD17B10 1528/4885 |
| US-20160184316-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 1101/4885ALDH1A1 2644/4885HSD17B10 3448/4885 |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 1031/4885ALDH1A1 2945/4885HSD17B10 3646/4885 |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | TSHR 1971/4885ALDH1A1 1125/4885HSD17B10 3160/4885 |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TSHR 807/4885ALDH1A1 2776/4885HSD17B10 4056/4885 |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | TSHR 2177/4885ALDH1A1 2216/4885HSD17B10 2489/4885 |
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | TSHR 4049/4885ALDH1A1 1326/4885HSD17B10 2052/4885 |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | HTR1A, HTR2C, CHRM1 | TSHR 72/4885ALDH1A1 2512/4885HSD17B10 1528/4885 |
| US-20030022904-A1 | Pyrazine compounds | CBR1, CBR3, NPY1R | TSHR 277/4885ALDH1A1 2653/4885HSD17B10 1953/4885 |
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | TSHR 385/4885ALDH1A1 1516/4885HSD17B10 3265/4885 |
| US-10053417-B2 | Neprilysin inhibitors | MME, REN, ACE | TSHR 931/4885ALDH1A1 3584/4885HSD17B10 3918/4885 |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | TSHR 4379/4885ALDH1A1 1473/4885HSD17B10 93/4885 |
| US-20170217961-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | TSHR 3700/4885ALDH1A1 127/4885HSD17B10 1093/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | TSHR 3245/4885ALDH1A1 1152/4885HSD17B10 201/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | TSHR 1031/4885ALDH1A1 2945/4885HSD17B10 3646/4885 |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD17B1, HSD17B2, HSD3B2 | TSHR 2784/4885ALDH1A1 105/4885HSD17B10 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.